Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2597-2602

  Li, Yanbing ^a   Xu, Wen ^a   Liao, Zhihong ^a   Yao, Bin ^a   Chen, Xiahua ^a   Huang, Zhimin ^a   Hu, Guoliang ^a   Weng, JianPing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN;

ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES CONTROL; DIETARY INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; REMISSION; SIDE EFFECT;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPIDS; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 7444234167     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2597     Document Type: Article

References (22)

1. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH: A two-step model for development of non-insulin-dependent diabetes. Am J Med 90:229-235, 1991
2. Robertson RP, Harmon J, Tran PO, Poitout V: β-Cell glucotoxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 (Suppl. 1):S119-S124, 2004
3. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
4. Samanta A, Burden AC, Jones GR, Clarkson L: The effect of short-term intensive insulin therapy in non-insulin-dependent diabetes who had failed on sulphonylurea therapy. Diabetes Res 3:269-271, 1986
5. Yki-Jarvinen H, Esko N, Eero H, Taskmo MR: Clinical benefits and mechanisms of sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 84:185-192, 1988
6. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E: improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinol 118:365-373, 1988
7. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27:1028-1032, 2004
8. Li Y, Xu W, Liao Z, Yao B, Huang Z, Weng J: The effect of continuous subcutaneous insulin infusion (CSII) on glucose metabolism and induction of long-term glycemic control in newly diagnosed type 2 diabetic patients (Abstract). Diabetes 53 (Suppl. 2):A112, 2004
9. Weng J, Li Y, Xu W, Chen X, Liao Z, Yao B, Deng W, Ou X, Hu G: The effect of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients. Chinese Journal of Diabetes 11:10-15, 2003
10. Zhu F, Ji L, Han X, Zhu Y, Zhang H, Zhou X, Chen J, Cai X, Zhang M: Induction of long-tern glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Chinese Journal of Diabetes 11:5-9, 2003
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
12. Gorden P, Hendricks CM, Roth J: Circulating proinsulin-like component in man: increased proportion in hypoinsulinemia state Diabetologia 10:469-474, 1974
13. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229, 1976
14. Weyer C, Tataranni PA, Bogardus C, Pratley RE: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89-94, 2001
15. Leahy JL, Bonner-Weir S, Weir GC: β-Cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15:442-455, 1992
16. Gleason CE, Gonzalez M, Harmon JS, Robertson RP: Determinants of glucotoxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab 279:E997-E1002, 2000
17. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20:1353-1356, 1997
18. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA: Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 18:10-16, 2001
19. Byrne MM, Sturis J, Sobel RJ, Polonsky KS: Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function. Am J Physi 270:E572-E579, 1996
20. Ryan EA, Imes S, Liu D, McManus R, Finegood DT, Polonsky KS, Sturis J: Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506-512, 1995
21. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA 281:2005-2012, 1999
22. Della Casa L, del Rio G, Glaser B, Cerasi E: Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia. Am J Med 90 (Suppl. 6A):37S-45S, 1991